Overview

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase II trial, assessing the antitumor activity, and safety of temozolomide in combination with O6-BG in patients with temozolomide-resistant anaplastic glioma.
Phase:
Phase 2
Details
Lead Sponsor:
Keryx / AOI Pharmaceuticals, Inc.
Treatments:
Dacarbazine
O(6)-benzylguanine
Temozolomide